Skip to main content
. 2021 May 14;13(5):1664. doi: 10.3390/nu13051664

Figure 1.

Figure 1

Prostate cancer patients receiving ADT can develop sarcopenic obesity due to a treatment-induced increase in fat mass and decrease in lean mass. These respective body composition changes can lead to poor patient outcomes. Images created with BioRender.com (accessed on 20 November 2020).